Evidence map›Paper›PMID 41924135›Full record

ArticleFrontiers in pharmacology2026

Targeting the AKT/mTOR axis: pectolinarigenin induces autophagy and apoptosis in human cervical cancer cells.

Yaoyao Fang, Jing Bai, Sijia Bo, Xiaoli Cui, Haiping Song, Li Guo, Zhaohui Luan, Qixuan Sui, Yingchun Zheng, Li Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Targeting Cancer Hallmarks withInternational journal of molecular sciences · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yaoyao Fang *The First Affiliated Hospital of Hainan Medical University, Hainan Medical University, Haikou, China.
Jing Bai *Department of Maternity, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan Maternity and Child Care Hospital, Jinan, China.
Sijia BoSchool of Clinical Medicine, Shandong Second Medical University, Weifang, China.
Xiaoli CuiSchool of Clinical Medicine, Shandong Second Medical University, Weifang, China.
Haiping SongFirst Department of Gynecology Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, China.
Li GuoQingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.
Zhaohui LuanFirst Department of Gynecology Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, China.
Qixuan SuiFirst Department of Gynecology Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, China.
Yingchun ZhengFirst Department of Gynecology Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, China.
Li SunFirst Department of Gynecology Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer (CC) remains a significant global health issue, accounting for approximately 7% of all cancer cases in women. This study investigated the anti-cancer potential of pectolinarigenin (PEC), a bioactive compound derived from plants, aiming to explore its therapeutic effects and underlying mechanisms against CC. By integrating network pharmacology analysis with cellular assays, we identified 13 key targets of PEC related to CC, with molecular docking highlighting AKT as a primary target. Experimentally, PEC demonstrated strong anti-cancer effects on cervical cancer both

Indexed as

Akt/mTOR signaling pathwayapoptosis and autophagycervical cancernetwork pharmacologypectolinarigenin

Identifiers

PMID41924135
PMCPMC13036129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.